Taysha Plans To Withhold Rett Results Until FDA Reviews Its Earlier Filing Case

Six-month results could bring an approval application forward by at least two full quarters, management said.

Share
Taysha Plans To Withhold Rett Results Until FDA Reviews Its Earlier Filing Case

Taysha Gene Therapies, which develops gene therapies for severe brain and spinal-cord diseases, plans to withhold interim Rett syndrome results until FDA feedback can accompany them, Chief Executive Officer Sean Nolan said on Thursday’s earnings call. The company hopes six-month trial data could support an approval application at least two full quarters earlier than a submission based on 12-month results.

January Silence, Then FDA Feedback

Nolan said management expects to “go dark” sometime in January once the interim results are available, staying out of public discussions until its FDA meeting and feedback. His reason: “the opinion that matters the most here is going to be the FDA's.”

The final patient’s six-month assessment, scheduled for December, will trigger the analysis. Reviewers must then assess patient videos before management receives the main trial results and secondary measures and requests the regulatory meeting.

Nolan anticipates that meeting later in the first quarter of 2027, assuming patient appointments and data processing stay on schedule. Written feedback could arrive in that quarter or early in the second quarter; Taysha plans to release results and regulatory direction in the first half of 2027.

Investors will receive the clinical evidence together with the agency’s view on whether it can support an earlier application. Nolan said that approach would let management explain either a six-month filing route or a requirement to wait for 12-month data.

Six Months Must Support The Case

A Wells Fargo analyst asked what evidence could persuade the FDA to allow the earlier filing. Nolan said roughly a third of patients must respond to meet the statistical threshold, but the agency would consider the full evidence package.

Taysha plans to show regulators the pivotal trial’s main and secondary measures, longer-term findings from its earlier trial and updated safety observations. Nolan argued that durable responses in the earlier study could strengthen the case if the pivotal results resemble them.

He described the request as a departure from the FDA’s usual preference for 12-month data, while explicitly separating that assessment from any agency objection. “They've never expressed this to us. They have not,” Nolan said of concern about precedent. The FDA has not decided whether the six-month findings can support an application.

The interim review will use only each patient’s first six months, even when longer follow-up is available. Two videos recorded before treatment and three afterward will enter the blinded review for each patient; later observations will remain blinded for the 12-month assessment.

Nolan committed to publishing the 12-month results even if Taysha files earlier. He said payer discussions suggested no reimbursement obstacle to full approval based on six-month evidence, provided the findings are strong enough for submission.

Launch Preparations Precede The Readout

Taysha’s lead program, TSHA-102, targets Rett syndrome, a rare disorder affecting development, communication and movement. The experimental one-time treatment delivers a functional MECP2 gene; it is central to the company’s work on central nervous system diseases, described in its Thursday corporate update.

Nolan said all 33 treated patients had passed the acute post-treatment safety-monitoring period. Across the program, no severe treatment-related serious adverse events or dose-limiting toxicities had been reported at the November 2026 cutoff.

Taysha has completed its commercial-scale manufacturing validation campaign under a strategy agreed with the FDA in January 2026. Management said the batches met product specifications and criteria for comparability with clinical material. A manufacturing discussion with the FDA is planned for the fourth quarter.

Payer conversations began in 2025, and Taysha has expanded its market-access team and worked on treatment-site, distribution and launch preparations. Nolan said the company expects no launch supply constraint.

Chief Financial Officer Kamran Alam reported $422.8 million in cash and cash equivalents as of September 30, 2026. Management expects those resources to fund planned operating expenses and capital needs into the second half of 2028.

The December patient assessment starts the interim review. Whether that review supports an earlier application will depend on the results and the FDA’s response.

Sources

More on Taysha Gene Therapies

All Taysha Gene Therapies (TSHA) coverage →